Edition:
United Kingdom

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

72.50GBp
18 Apr 2019
Change (% chg)

0.20 (+0.28%)
Prev Close
72.30
Open
70.60
Day's High
73.10
Day's Low
70.60
Volume
896,288
Avg. Vol
928,686
52-wk High
107.80
52-wk Low
65.85

About

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) -... (more)

Overall

Beta: 0.41
Market Cap(Mil.): £705.16
Shares Outstanding(Mil.): 679.34
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -- -- --
ROI: -- 14.23 13.83
ROE: -- 15.46 15.25

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

03 Jan 2019

Vectura hopes new respiratory device will breathe life into business

Vectura Group is pinning its future on a relatively new respiratory device aimed at treating several ailments beyond asthma, as the British drugmaker looks to revive its business after the costly acquisition of rival SkyePharma in 2016.

03 Jan 2019

UPDATE 3-Vectura hopes new respiratory device will breathe life into business

* Forecasts 2018 adjusted core earnings above market forecasts

03 Jan 2019

UK drugmaker Vectura expects 2018 earnings to top market forecasts

Jan 3 British drugmaker Vectura Group Plc on Thursday predicted that its adjusted earnings in 2018 would top market expectations, helped in part by improving profit margins.

03 Jan 2019

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

26 Nov 2018

Vectura drops severe asthma treatment after poor trial results

Britain's Vectura Group Plc will stop developing its treatment for severe uncontrolled asthma after a trial showed it failed to have a significant impact on the condition.

26 Nov 2018

UPDATE 2-Vectura drops severe asthma treatment after poor trial results

* Shares fall more than 10 percent (Adds CEO, analyst comment, share movement)

26 Nov 2018

Vectura to stop developing asthma treatment after late-stage failure

Nov 26 British drugmaker Vectura Group Plc said on Monday it would stop developing its treatment for severe uncontrolled asthma after the drug-device combination failed to meet the main goal of a late-stage study.

26 Nov 2018

Earnings vs. Estimates